Drug Trial Radar · NCT06070532
A Study of Human Allogeneic Bone-marrow-derived Mesenchymal Stromal Cell Product (StromaForte) in Patients With Aging Frailty
Last checked: Nov 19, 2026Latest source record: Apr 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Jan 1, 2025
Primary completion
Jan 1, 2026
Study completion Jan 10, 2027
Sponsor
- Lead sponsor
- Cellcolabs Clinical LTD.Industry
- Sponsor type
- Industry
- First posted
- Oct 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 60 years, up to 85 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this phase I/II clinical trial is to evaluate the safety and tolerability of intravenous infusion of human allogeneic bone-marrow-derived mesenchymal stromal cell product StromaForte in patients with aging frailty. The main questions it aims to answer are: To assess the safety and tolerability after 28 days of injection by reporting the number of adverse events assessed by Common Terminology Criteria For Adverse Events (CTCAE) Observe the change in inflammatory markers from baseline to 6 months (baseline to 28, 84, and 168 days post-infusion.) Participants will receive 100 x 106 allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion 100 million cells in approximately 30 min
Conditions
- Frailty
Interventions
Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)Biological
100 x 106 allogeneic bone marrow (BM)-derived Mesenchymal Stromal Cell (MSC) formulated in sodium chloride supplemented with human serum albumin to be given via slow intravenous infusion 100 million cells in approximately 30 min
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of intravenous infusion of human allogeneic bone-marrow-derived mesenchymal stromal cell product StromaforteTime frame: Post 28 day infusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
To be decided
Nassau, The Bahamas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.